Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Taiho Ties Up with Nordic Group to Commercialize TS-1 in Europe
August 1, 2011
- PMDA Establishes Coordinating Organization to Prepare for PIC/S Membership
August 1, 2011
- Eisai's Halaven “Extremely Convenient for Outpatients”: Dr Iwata of Aichi Cancer Center
August 1, 2011
- Equa Ranked No. 1 Both in HP, GP Markets for 2nd Straight Month: RepTrack Survey
August 1, 2011
- Generic Drugmakers Still Reluctant to File for Add'l Indications Based on Info in Public Domain
August 1, 2011
- JPA Urges Member Pharmacies to Participate in JCQHC-initiated Accident Reporting Project
August 1, 2011
- Japanese Pharm. Industry Needs Aggressive Globalization: Dr Kato of EFPIA Japan
August 1, 2011
- Premium for New Drug Development Should Be Made Permanent: Mr Wolf of PhRMA
August 1, 2011
- Asahi Kasei to Enter Market for Medical Devices for Emergency Care Aiming at ¥100 Bil. Sales
August 1, 2011
- Shionogi to Acquire 9 Products from Victory Pharma of the US
August 1, 2011
- FDA's Advisory Committee Does Not Recommend Approval of Dapagliflozin
August 1, 2011
- Korosho, PMDA Providing Risk Info on Drugs Under Review on Websites
August 1, 2011
- LTT Bio-Pharma to License Inhalant PC-SOD to CKD in South Korea
August 1, 2011
- Transfer of Part of PMDA Functions to Osaka Proposed in Kansai Sogo Tokku Plan
August 1, 2011
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
- Chugai Applies for Approval of Pulmozyme for Cystic Fibrosis
August 1, 2011
- Mochida, MTPC to Launch Lexapro on Aug. 22
August 1, 2011
- Sodium Phenylbutyrate from CMIC Designated as Orphan Drug
August 1, 2011
- BMKK to Take the Offensive with 1st-line CML Treatment Sprycel
July 25, 2011
- Combinational Use of Avastin, Xeloda Approved in Europe: Roche
July 25, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…